Key Trend Reshaping the Liraglutide Market in 2025: Expansion Of Generic GLP-1 Products In The Liraglutide Market

What combination of drivers is leading to accelerated growth in the liraglutide market?
The increasing diabetic population is expected to propel the liraglutide market. Diabetes, particularly type 2, is on the rise due to factors like sedentary lifestyles, unhealthy diets, and obesity. Liraglutide, a drug that mimics the GLP-1 hormone to regulate blood sugar, plays a significant role in managing diabetes. In March 2023, the UK's NHS reported a rise in type 1 diabetes care processes, signaling a growing need for diabetes management. This surge in diabetes cases is driving the liraglutide market.

Get Your Liraglutide Market Report Here:
https://www.thebusinessresearchcompany.com/report/liraglutide-global-market-report

What is the projected compound annual growth rate (CAGR) of the liraglutide market from 2025 to 2034, and what factors influence it?
The liraglutide market will grow from $6.38 billion in 2024 to $6.95 billion in 2025 at a CAGR of 9.0%, supported by increasing type 2 diabetes cases, obesity rates, and innovations in diabetes treatments.

The liraglutide market is projected to reach $9.66 billion by 2029, growing at a CAGR of 8.6%. Growth is attributed to healthcare infrastructure development, rising diabetes prevalence, and expanding insurance coverage. Trends include AI-driven research, wearable technology integration, continuous glucose monitoring, and digital health platform advancements.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18659&type=smp

How are the latest trends influencing the growth of the liraglutide market?
Major companies in the liraglutide market are introducing new products like generic GLP-1 drugs to expand treatment options and meet the growing demand for affordable alternatives. Generic GLP-1 drugs are versions of GLP-1 receptor agonists that are produced once the patent for the original branded medications expires, offering a more cost-effective treatment option for conditions like type 2 diabetes and obesity. For instance, in June 2024, Teva Pharmaceutical Industries Ltd., an Israeli pharmaceutical company, launched the first generic version of GLP-1, similar to Victoza, in the U.S. This new option aims to meet the increasing demand for these therapies, offering liraglutide injections to manage blood sugar in adults and children over 10 with type 2 diabetes, and to reduce the risk of cardiovascular events in adults with both type 2 diabetes and heart disease.

What are the major segments of the liraglutide market and their role in driving growth?
The liraglutide market covered in this report is segmented -

1) By Brands: Victoza, Saxenda
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies And Drug Stores, Online Pharmacies
3) By Type Of Application: Diabetes Treatment, Weight Management
4) By End-Users: Hospitals And Clinics, Homecare Settings

Subsegments:
1) By Victoza: Type 2 Diabetes Treatment Or Weight Management
2) By Saxenda: Weight Loss Treatment Or Obesity Management

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18659

Which regions are key players in the growth of the liraglutide market?
North America was the largest region in the liraglutide market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the key firms paving the way for growth in the liraglutide market?
Major companies operating in the liraglutide market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Biocon Limited, Hanmi Pharmaceutical Co. Ltd., Intarcia Therapeutics Inc., Adocia SA

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=18659&type=smp

What Is Covered In The Liraglutide Global Market Report?

•Market Size Forecast: Examine the liraglutide market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the liraglutide market for a structured understanding.
•Key Players Overview: Analyze major players in the liraglutide market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the liraglutide market.
•Segment Contributions: Evaluate how different segments drive overall growth in the liraglutide market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the liraglutide market.
•Industry Challenges: Identify potential risks and obstacles affecting the liraglutide market.
•Competitive Landscape: Review strategic developments in the liraglutide market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.